Shares of Neos Therapeutics Inc (NASDAQ:NEOS) have received an average recommendation of “Hold” from the nine analysts that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $15.33.
Several research analysts have weighed in on NEOS shares. BidaskClub raised Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Cantor Fitzgerald set a $20.00 target price on Neos Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 8th. BMO Capital Markets lowered Neos Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 31st. Finally, Zacks Investment Research lowered Neos Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th.
Neos Therapeutics (NASDAQ:NEOS) opened at $9.00 on Tuesday. The company has a debt-to-equity ratio of 4.01, a current ratio of 2.42 and a quick ratio of 2.14. Neos Therapeutics has a 52-week low of $6.30 and a 52-week high of $13.15. The firm has a market capitalization of $259.52, a PE ratio of -2.63 and a beta of -0.20.
COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/13/neos-therapeutics-inc-neos-given-average-rating-of-hold-by-analysts.html.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.